The closing price of Standard BioTools Inc (NASDAQ: LAB) was $2.77 for the day, down -0.72% from the previous closing price of $2.79. On the day, 2168804 shares were traded.
Ratios:
Our analysis of LAB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.26 and its Current Ratio is at 1.45. In the meantime, Its Debt-to-Equity ratio is 0.60 whereas as Long-Term Debt/Eq ratio is at 0.21.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on April 04, 2024, initiated with a Buy rating and assigned the stock a target price of $3.25.
On July 12, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $4.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 05 ’24 when Casdin Partners Master Fund, L bought 1,403 shares for $2.62 per share. The transaction valued at 3,669 led to the insider holds 11,497,928 shares of the business.
Casdin Partners Master Fund, L bought 250,000 shares of LAB for $642,500 on Mar 04 ’24. The Director now owns 11,496,525 shares after completing the transaction at $2.57 per share. On May 19 ’23, another insider, Casdin Eli, who serves as the Director of the company, bought 800,000 shares for $2.29 each. As a result, the insider paid 1,835,920 and bolstered with 1,200,000 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 9.98.
Stock Price History:
Over the past 52 weeks, LAB has reached a high of $3.16, while it has fallen to a 52-week low of $1.46.
Shares Statistics:
A total of 383.05M shares are outstanding, with a floating share count of 369.48M. Insiders hold about 3.54% of the company’s shares, while institutions hold 48.33% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by Rocket Lab USA, Inc. analysts. The consensus estimate for the next quarter is $120.50, with high estimates of $108.89 and low estimates of $97.76.
EPS for the following year is $Stocks, with Stocks analysts recommending between $Stocks and $ETF.
